scholarly journals Topical 100% Serum Eye Drops for Treating Corneal Epithelial Defect after Ocular Surgery

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Kaevalin Lekhanont ◽  
Passara Jongkhajornpong ◽  
Lulin Choubtum ◽  
Varintorn Chuckpaiwong
Keyword(s):  
Complete Healing ◽  
Autologous Serum ◽  
Eye Drops ◽  
Epithelial Defect ◽  
Ocular Surgery ◽  
Corneal Epithelial ◽  
Corneal Epithelial Defect ◽  
Conventional Medical Therapy ◽  
Serum Eye Drops

The purpose of this study was to investigate the efficacy and safety of topical 100% serum eye drops for corneal epithelial defect after ocular surgery. A total of 181 patients who received topical 100% serum therapy for the treatment of corneal epithelial defect following several different types of ocular surgery were recruited into this study. Each patient already failed conventional medical therapy before being prescribed 100% serum eye drops. Slit-lamp biomicroscopic examination with fluorescein staining was performed at baseline and all follow-up visits. The main outcome measures were the rate of complete healing of the corneal epithelial defect and incidence of adverse events. One hundred and seventy-eight eyes (98.34%) received autologous serum eye drops, and 3 (1.66%) received allogeneic serum eye drops. The overall success rate of treating persistent postoperative epithelial defect using 100% serum eye drops was 93.92% (95% CI 0.88–0.98). The median time to complete corneal epithelialization was 4 days (95% CI 4-5). Adverse reactions were observed in 3 patients (1.66%), including sticky sensation with minimal eye discomfort and asymptomatic trace corneal subepithelial infiltration. No serious complications were reported. In conclusion, 100% serum eye drops are effective, safe, and tolerable for treating postoperative corneal epithelial defect following ocular surgeries.

scholarly journals Autologous Serum Eye Drops for Post-Chemical Injuries and Corneal Epithelial Defects

2013 ◽  
Vol 1 (1) ◽  
pp. 45-49
Author(s):  
Mirjana A. Janicijevic-Petrovic ◽  
Marko Petrovic ◽  
Dragan Vujic ◽  
Katarina Janicijevic ◽  
Andrijana Popovic
Keyword(s):  
Success Rate ◽  
Conventional Treatment ◽  
Complete Healing ◽  
Autologous Serum ◽  
Eye Drops ◽  
Epithelial Defect ◽  
Corneal Epithelial ◽  
Chemical Injuries ◽  
Serum Therapy ◽  
Serum Eye Drops

Aim: To evaluate success rate (efficacy, safety) in treatment of post-chemical injuries and corneal defects using autologous serum eye drops.Material and Methods: Authors reviewed 93 patients (116 eyes) hospitalized in Clinic of ophthalmology from 2010 to 2013, who had post-causoma corneal defects that were nonresponsive to conventional treatment and were treated with serum therapy. Authors correlated time of epithelialization of defects with rate of epithelial healing.Results: Authors investigated 93 patients (52 males, 41 females; aged 18 - 74) for treatment of corneal defects. Application of autologous serum therapy 56 (48.28%) of 116 eyes was healed in an average time of 4 weeks. Among 116 eyes, epithelial defects healed in 4 (3.45%) within 1 week, in additional 17 (14.65%) in 1-2 weeks, totalling 31 (26.72%) within 3 weeks. Five eyes (4.31%) completely healed at 5 week; three eyes (2.59%) had subsequent healing of epithelial defect at 6 week; 56 eyes completely healed within one month, and the remaining eight eyes healed within 1.5 month.Conclusion: Using serum therapy, it was managed to reduce time of healing from eleven weeks, which were necessary just couple years ago (before 2010) to four (maximum six) weeks to complete healing which are necessary today.

scholarly journals Erratum to “Topical 100% Serum Eye Drops for Treating Corneal Epithelial Defect after Ocular Surgery”

2014 ◽  
Vol 2014 ◽  
pp. 1-1
Author(s):  
Kaevalin Lekhanont ◽  
Passara Jongkhajornpong ◽  
Lulin Choubtum ◽  
Varintorn Chuckpaiwong
Keyword(s):  
Eye Drops ◽  
Epithelial Defect ◽  
Ocular Surgery ◽  
Corneal Epithelial ◽  
Corneal Epithelial Defect ◽  
Serum Eye Drops

scholarly journals Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect

Eye ◽  
2008 ◽  
Vol 23 (2) ◽  
pp. 290-293 ◽  
Author(s):  
C-C Chiang ◽  
W-L Chen ◽  
J-M Lin ◽  
Y-Y Tsai
Keyword(s):  
Eye Drops ◽  
Epithelial Defect ◽  
Corneal Epithelial ◽  
Corneal Epithelial Defect ◽  
Serum Eye Drops

scholarly journals Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Maria Rosaria De Pascale ◽  
Michele Lanza ◽  
Linda Sommese ◽  
Claudio Napoli
Keyword(s):  
Human Serum ◽  
Clinical Studies ◽  
Tear Film ◽  
Eye Drops ◽  
Corneal Epithelial ◽  
Activated Platelets ◽  
Open Debate ◽  
Potential Benefits ◽  
Serum Eye Drops

Human serum contains a physiological plethora of bioactive elements naturally released by activated platelets which might have a significant effect on the regeneration of corneal layers by stimulating the cell growth. This mechanism supported the use of human serum eye drops in some ocular diseases associated with dystrophic changes and alterations of the tear film, such as persistent corneal epithelial defects and dry eye syndrome. We focused our effort on potential benefits and limitations of the use of human serum eye drops when conventional therapies failed. We reviewed the recent literature by reporting published studies from 2010 to 2014. Despite the limited evaluated study populations, most of the clinical studies have confirmed that serum eye drop therapy is effective in corneal healing by reducing ocular symptom, particularly during the short-term follow-up. In addition, three recent published studies have shown the efficacy of the serum eye drop therapy in comparison to traditional ones in intractable patients. Besides, reported ongoing clinical studies confirmed the open debate regarding the use of biologic tools for cornea regeneration. Results from these studies might open novel challenges and perspectives in the therapy of such refractory patients.

Treatment of persistent epithelial defects with single-dose autologous serum eye drops

2021 ◽  
pp. 112067212110483
Author(s):  
Selma Özbek-Uzman ◽  
Züleyha Yalnız-Akkaya ◽  
Evin Şingar Özdemir ◽  
Ayşe Burcu
Keyword(s):  
Single Dose ◽  
Healing Time ◽  
Autologous Serum ◽  
Eye Drops ◽  
Artificial Tears ◽  
Duration Of Treatment ◽  
The Mean ◽  
Preservative Free ◽  
Serum Eye Drops

Purpose: We aimed to investigate the efficacy and safety of single-dose autologous serum eye drops (ASEDs) for treatment of persistent corneal epithelial defects (PEDs). Methods: About 34 eyes of 26 patients treated from March 2016 to May 2020 with a single dose of ASEDs for PEDs that did not respond to conventional treatment were retrospectively evaluated. Patient demographics, predisposing factors, size, and duration of the PED, duration of treatment, and dosage of ASEDs, PED healing time, success rate of the ASED treatment, and follow-up time after the onset of ASED treatment were recorded. Autologous serum eye drops (20%) were prepared by diluting the serum with preservative-free artificial tears in single-dose vials. Vials were stored at −20°C and used daily after dissolving. Results: The mean patient age was 47.0 ± 18.5 years, and 13 (50%) of the patients were male. The most common indication for ASEDs was PED after keratoplasty. The mean duration of ASED treatment was 8.5 ± 6.3 months, and mean follow-up time was 22.8 ± 12.2 months. Autologous serum eye drop treatment was effective in 25 (73.5%) eyes and partially effective in 5 (14.7%) eyes. None of the eyes displayed complications related to the treatment. Conclusion: In patients with PED for whom conservative treatment is insufficient, ASEDs prepared by dilution with preservative-free artificial tears in single-dose vials and administered based on the daily use principle appear to be effective and safe.

scholarly journals APPLICATION OF AUTOLOGOUS SERUM EYE DROPS AFTER PTERYGIUM SURGERY

2021 ◽  
Vol 71 (5) ◽  
pp. 1563-66
Author(s):  
Hassan Sajjad Rathore ◽  
Ahsan Mukhtar ◽  
Shahzad Saeed ◽  
Umar Ijaz ◽  
Mamoona Javaid ◽  
...  
Keyword(s):  
Corneal Epithelium ◽  
Healing Time ◽  
Complete Healing ◽  
Autologous Serum ◽  
Military Hospital ◽  
Eye Drops ◽  
Cross Sectional ◽  
Conjunctival Inflammation ◽  
Pterygium Surgery ◽  
Serum Eye Drops

Objective: To compare the corneal epithelium healing time and post-operative pain after pterygium surgery with and without he use of autologous serum drops. Study Design: Comparative cross-sectional study. Place and Duration of Study: Eye Department, Combined Military Hospital Quetta, from Jan to Aug 2019. Methodology: Twenty patients were included in this study and divided into two groups. All patients underwent pterygium excision with conjunctival autograft. Fourteen of them were instilled with autologous serum drops while 14 were given lubricants postoperatively until corneal epithelium healed completely. Corneal epithelium healing time, visual analog scale for postoperative pain assessment, conjunctival inflammation and recurrences were evaluated. Patients were followed up for 6 months. Results: For corneal epithelial healing, 1 (7.14%) patient showed complete healing on day 2 while 7 (50%) showed healing on day 3 and 6 (42.86%) on day 4. While in non-autologous serum drops group 7 (50%) showed complete healing on day 4 while 4 (28.57%) showed healing on day 5 and 3 (21.43%) on day 6. The mean corneal healing time of autologous serum drops group was 3.36 ± 0.63 days and that of non-autologous serum drops group was 4.71 ± 0.83 days. Patients of autologous serum drops group also experienced significantly less pain as compared to the non-autologous serum drops group. While the recurrence rate and conjunctival inflammation in the two groups was found to be of equal degree. Conclusion: Patients who used autologous serum eye drops post operatively experienced less pain and their corneal epithelium healed earlier than the.......

Topical insulin for refractory persistent corneal epithelial defects

2020 ◽  
pp. 112067212095830
Author(s):  
David Diaz-Valle ◽  
Barbara Burgos-Blasco ◽  
Jose A Gegundez-Fernandez ◽  
Sara Garcia-Caride ◽  
Virginia Puebla-Garcia ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Healing Time ◽  
Bullous Keratopathy ◽  
Eye Drops ◽  
Ocular Surgery ◽  
Corneal Epithelial ◽  
Area Reduction ◽  
Mean Time ◽  
Persistent Epithelial Defects

Purpose: To evaluate insulin eye drops for persistent epithelial defects (PEDs) that are refractory to usual treatment in clinical practice and to analyze how it may improve epithelization. Methods: A prospective non-randomized hospital-based study was performed. Patients with PEDs that were refractory to conventional treatment were treated with insulin eye drops four times a day. Patients’ demographics, PED etiology, concomitant treatments, and comorbidities were reviewed. The rate of PED closure and epithelial healing time were considered the primary outcome measures. Results: 21 patients were treated with insulin drops (12 females and 9 males; mean age 72.2 years). Mean PED area before treatment was 17.6 ± 16.5 mm2 (median 13.2; range 3.9–70.6). PED comorbidities included seven eyes with infectious keratitis (33%), five eyes with calcium keratopathy (24%), ocular surgery on three eyes (14%), three eyes with lagophthalmos (14%), two eyes with bullous keratopathy (10%), and one patient with herpetic eye disease (5%). The eyes of 17 patients (81%) with refractory PEDs had reepithelized and four patients (19%) had still presented an epithelial defect by the end of the study follow-up period, although it had decreased in size. In patients where PED closure was achieved, mean time until reepithelization was 34.8 ± 29.9 days (median 23; range 7–114). In the remaining patients, a mean area reduction of 91.5% was achieved for the PEDs. Conclusion: Topical insulin can promote and accelerate corneal reepithelization of refractory PEDs. It also offers many other advantages, including excellent tolerance, availability, and cost-effectiveness.

scholarly journals A Case of Neurotrophic Keratopathy Associated with Nasopharyngeal Carcinoma

2018 ◽  
Vol 9 (1) ◽  
pp. 114-118 ◽  
Author(s):  
Tomoko Sato ◽  
Koji Sugioka ◽  
Aya Kodama-Takahashi ◽  
Masahiko Fukuda ◽  
Hiroshi Mishima ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cavernous Sinus ◽  
Visual Disturbance ◽  
Amniotic Membrane Transplantation ◽  
Eye Drops ◽  
Epithelial Defect ◽  
Corneal Epithelial ◽  
Corneal Epithelial Defect ◽  
Defect Area ◽  
Neurotrophic Keratopathy

Purpose: To report a case of neurotrophic keratopathy associated with nasopharyngeal carcinoma. Case Report: A 59-year-old man who had been diagnosed with a nasopharyngeal carcinoma was referred to the authors because of visual disturbance and pain in his right eye. Slit-lamp examination revealed a corneal epithelial defect and corneal stromal edema surrounding the epithelial defect area in his right eye. Magnetic resonance imaging showed a mass in his cavernous sinus, which was identified as nasopharyngeal carcinoma (NPC). We diagnosed neurotrophic keratopathy associated with NPC and initiated treatment with preservative-free artificial tears, antibiotic eye drops, fibronectin, a therapeutic contact lens, and amniotic membrane transplantation. However, the persistent corneal epithelial defect was unresponsive to these treatments. Conclusion: Neurotrophic keratopathy secondary to NPC is thought to be rare. We presented a case of neurotrophic keratopathy associated with cavernous sinus metastasis of an NPC. The development of new and more effective treatments for this refractory disease is anticipated.

Efficacy of honey based ophthalmic formulation in patients with corneal ulcer; A randomized clinical trial

2020 ◽  
Vol 17 ◽  
Author(s):  
Mahmood Nejabat ◽  
Kazem Soltanzadeh ◽  
Masoud Yasemi ◽  
Saeid Daneshamouz ◽  
Amin Reza Akbarizadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Foreign Body ◽  
Randomized Clinical Trial ◽  
Standard Treatment ◽  
Corneal Ulcer ◽  
Complete Healing ◽  
Epithelial Defect ◽  
Corneal Epithelial ◽  
Corneal Epithelial Defect ◽  
Ophthalmic Formulation

Aim: The aim of this study was to evaluate the efficacy of honey-based ophthalmic drop in patients with foreign body induced corneal ulcer. Background: Honey is traditionally used for the skin, mucosal and corneal ulcers. Its use is well studied in human skin and mucosal ulcers and animal model of corneal ulcer with promising effects. Methods: In this randomized clinical trial, 50 patients with foreign body induced corneal ulcer were allocated to receive 70% sterile honey-based ophthalmic formulation or 0.3% ophthalmic ciprofloxacin, as the standard treatment every 6 hours. All patients were examined for the size of corneal epithelial defect, corneal infiltration and depth and followed on a daily basis until complete healing. Duration for complete healing was considered as the outcome measure. Smear, culture, antibiogram and minimum inhibition concentration (MIC) test were performed for honey and ciprofloxacin in all patients. Results: The average durations of complete healing of corneal epithelial defect in the honey and ciprofloxacin groups were 3.88 ± 3.44 vs. 6.32 ± 3.69days, respectively (p=0.020). No significant difference was observed between the two groups regarding the average duration of healing of corneal infiltration (8.12 ±1.94 days vs. 8.64±2.15 days, p=0.375). MIC of honey for pseudomonas aeruginosa was 60%w/w, for E.Coli 40% w/w, and for staphylococcus aureus 30% w/w. Conclusion: Honey based ophthalmic drop can acceleratethe corneal epithelial defect healing in patients with foreign body induced corneal ulcer, compared to ophthalmic ciprofloxacin as the standard treatment.

Sign in / Sign up

Export Citation Format

Share Document